Japan's MHLW approves CSL & Arcturus' updated sa-mRNA Covid-19 vaccine for ...
CSL and Arcturus Therapeutics received approval from Japan's MHLW for their updated sa-mRNA Covid-19 vaccine, Kostaive, targeting the JN.1 Omicron subvariants for adults 18 and older. Meiji Seika Pharma will distribute the vaccine in time for the October Covid-19 vaccination campaign, marking the world's first commercially available sa-mRNA Covid-19 vaccine for adults. The approval is based on clinical evidence supporting the vaccine's safety and effectiveness, with data showing superior immunogenicity to Omicron BA 4/5 and duration of immunity up to one year.
Reference News
CSL and Arcturus Therapeutics received approval from Japan's MHLW for their updated sa-mRNA Covid-19 vaccine, Kostaive, targeting the JN.1 Omicron subvariants for adults 18 and older. Meiji Seika Pharma will distribute the vaccine in time for the October Covid-19 vaccination campaign, marking the world's first commercially available sa-mRNA Covid-19 vaccine for adults. The approval is based on clinical evidence supporting the vaccine's safety and effectiveness, with data showing superior immunogenicity to Omicron BA 4/5 and duration of immunity up to one year.